[LFN's evaluation of Inspra illustrates the need of drug committees!].
Karolinska Universitetssjukhuset Solna.
Rickard
R
Malmström
Paul
P
Hjemdahl
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004346:Drug Information Services; D000077545:Eplerenone; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D010606:Pharmacy and Therapeutics Committee; D017410:Practice Guidelines as Topic; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000191:economics* / Q000627:therapeutic use; D013548:Sweden
D013148:Spironolactone; D000077545:Eplerenone